oncology-facility
test-solutions-for-cancer

Who We Are?

Datar Cancer Genetics is a leading multinational molecular oncology facility, started with a clear vision:

To transform cancer care through precision oncology.

Leveraging advanced molecular science, we aim to make non-invasive blood tests accessible for improved cancer management, especially for those facing advanced cancer.

Our easy-to-access tests enable patients to take swift action against cancer.

At Datar Cancer Genetics, we are dedicated to supporting you every step of the way with precision and care.

Our Mission

At Datar Cancer Genetics, we believe that relentless research, bold initiatives, sustained commitment, and an unwavering determination to overcome cancer are essential in making a meaningful impact. This dedication drives us to pioneer new methods and continuously innovate, focusing on the power of molecular oncology and personalised medicine to transform cancer care.

Our non-invasive blood-based tests are designed to help clinicians make informed, data-driven decisions, enabling personalised cancer therapies that improve patient outcomes. By staying at the forefront of precision oncology, we strive to bring cutting-edge and accessible solutions to patients worldwide.

Our products are CE-marked and meet the EU health, safety, and environmental requirements, which ensure patient safety. 

journey-milestones

Our Journey

Since our foundation in India, we have been dedicated to advancing non-invasive cancer detection and personalised therapies.

2013-2017

Began pioneering research on Circulating Tumour Cells (CTCs) to create non-invasive methods for early cancer detection and treatment guidance.

2018-2020

Expanded our reach to Germany and established a laboratory in the UK to bring our innovative solutions closer to patients worldwide.

2021

Reached key milestones, including FDA approval for TriNetra™- Breast, a blood test to screen for breast cancer, and UK recognition for Trublood™-Prostate, a non-invasive test for prostate cancer diagnosis.

Corporate Team

Mr Rajan Datar

MR. RAJAN DATAR

Promoter, Datar Cancer Genetics
[B.Sc., LLB]

Ms Swati Deshpande

Ms. SWATI DESHPANDE

Senior Director
[BSc, LLB, Healthcare Management (ISB)]

Dr Vineet Datta

Dr. VINEET DATTA

Senior Director
[MD, FRCP (Glasg.), MCEM, FRSPH (CMQ/ASG)]

Dr Darshana Patil

DR. DARSHANA PATIL

Senior Director
[MD (Pathology), MMO (CNIO)]

Ms Sneha Datar

Ms. SNEHA DATAR

Director
[LLB]

Dr Dadasaheb Akolkar

Dr. Dadasaheb Akolkar

Director, Research and Innovation
[PhD (Biotechnology), MMO (CNIO)]

Core Research Team

Prof Dr Raymond Page

Prof. Dr. Raymond Page

Chief Scientific Officer (USA)
[Chemical Engineering), PhD]

Dr Ajay Srinivasan

DR. Ajay Srinivasan

General Manager, Scientific Affairs and Communications
[PhD (Biotechnology)]

Clinical Support

India

Dr Ashwini Ghaisas1

Dr. Ashwini Ghaisas

Director, Applications
[MBBS, MRCOG, D OBS]

International

Dr Stefan Schuster1

Dr. Stefan Schuster

Managing Director, Europe
[PhD (Medicinal Chemistry)]

Lab and Medical Affairs

Dr Revati Patil

Dr. Revati Patil

Consultant Pathologist
[MD (Pathology)]

Dr Cynthe Sims

Dr. Cynthe Sims

Laboratory Director (CLIA)
[PhD (Chemistry)]

Dr Rahul Gosavi

Dr. Rahul Gosavi

Senior Manager
[MSc (Microbiology), PhD (Medical Microbiology)]

Dr Navin Shrivastava2

Dr. Navin Shrivastava

Laboratory Director
[PhD (Biochemistry)]

Advisors

Dr Tim Crook

Dr. TIM CROOK

Medical Oncologist
[BSc, PhD, MBBS, MRCP, FRCP]

Dr Andy Gaya

Dr. ANDY GAYA

Medical Oncologist
[MD, MRCP, FRCR]

Prof Dr Kefah Mokbel1

Prof. Dr. KEFAH MOKBEL

Breast Cancer Surgeon
[MS, FRCS]

Prof Dr Nick Plowman1

Prof. Dr. NICK PLOWMAN

Medical Oncologist
[MA, MD, FRCP, FRCR]

Dr Massimo Cristofanilli

Prof. Dr. Massimo Cristofanilli

Medical Oncologist
[MD, FACP]

Dr Sevanti Limaye

Dr. Sewanti Limaye

Medical Oncologist
[MBBS, MD, MS]

Dr Prem Pillai

Dr. Prem Pillai

Neurosurgeon
[MBBS, FRCS, FAMS (Neurosurgery), FRCS, FACS]

Dr Ashok Vaid

Dr. Ashok Vaid

Medical Oncology
[MBBS, MD (General Medicine), DM (Medical Oncology)]

Dr Nitesh Rohatgi

Dr. Nitesh Rohatgi

Medical Oncologist
[MBBS, DNB, MRCP, FRCP]

Dr Siddharth Sahani

Dr. Sidharth Sahni

Breast Cancer Surgeon
[MBBS, MRCS (UK)]

Dr Anantbhushan Ranade

Dr. Ananatbhushan Ranade

Medical Oncologist
[MBBS, MD]

Our Test Portfolio

To fulfill our vision, we have developed a range of non-invasive blood tests that provide personalised insights to guide cancer treatment, helping doctors make informed decisions tailored to each patient.

EasyCheck360®

EasyCheck360® is a non-invasive blood test that helps to detect multiple types of solid organ cancers at an early stage by identifying Circulating Tumour Cells (CTCs). It offers a safe, accurate, and radiation-free screening option.

KNOW MORE

Trublood™

Trublood™ is a no-risk alternative to traditional biopsies, offering a safe, accurate, and cost-effective method for detecting solid tumours (that occur in organ systems of the body) and brain tumours without any invasive procedures.

KNOW MORE

Exacta™

Exacta™ is a comprehensive genomic test designed to identify key genetic alterations and pathways driving the cancer, enabling us to understand which treatments might work best against it.

KNOW MORE

Pinaka™

Pinaka™ is a non-invasive blood test that detects Circulating Tumour Cells (CTCs) and analyses key biomarkers to guide personalised cancer treatment-especially when tissue samples are hard to obtain.

KNOW MORE

Celldx™

Celldx™ is a comprehensive genomic test to identify actionable therapy options based on guideline-recommended genes for tumours that occur in solid organ systems of the body.

KNOW MORE

Chemoscale™

Chemoscale™ is a non-invasive test that analyses tumour cells to evaluate how a chemotherapy drug may work or reveal potential resistance. This helps guide the selection of the most effective treatment.

KNOW MORE

Cancertrack™

Effective cancer management requires a proactive treatment approach that stays ahead of tumour growth. Traditional methods, like scans, can take over three months to indicate if a treatment is working for you.

KNOW MORE

Target-MRD™

Target-MRD™is a highly advanced blood test that detects minimal residual disease (MRD) using tumour-informed and tumour-agnostic methods to track cancer recurrence early and guide treatment decisions.

KNOW MORE

Our tests may be able to enhance your chances to win the battle against cancer through a smart combination of therapy guidance derived using multi-analyte analysis of the cancer cells.